Research map: Effectiveness of bimekizumab according to previous biologic exposure in patients with plaque psoriasis: a multicenter real-world study

Back to the article

Papers in this map

  1. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis · April Wang Armstrong · 2020 · 2351 citations · Cited by this paper
  2. Raising the bar of efficacy in Atopic Dermatitis: deep response in week 16 responders treated with lebrikizumab over 2 years · 2026 · Related
  3. The Immunologic Role of IL-17 in Psoriasis and Psoriatic Arthritis Pathogenesis · Andrew Blauvelt · 2018 · 795 citations · Cited by this paper
  4. Comparative efficacy and safety of platelet-rich plasma (PRP), injectable platelet-rich fibrin (i-PRF) and concentrated growth factors (CGF) for female pattern hair loss (FPHL): a prospective multicenter randomized clinical trial · 2026 · Related
  5. Bimekizumab versus Secukinumab in Plaque Psoriasis · Kristian Reich · 2021 · 428 citations · Cited by this paper
  6. Early response to ivarmacitinib and its impact on long-term efficacy in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase-III trial · 2026 · Related
  7. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial · Kenneth B. Gordon · 2021 · 295 citations · Cited by this paper
  8. Healthcare resource use of patients with mild-moderate psoriasis on systemic treatments: a UK single-center longitudinal retrospective cohort study · 2026 · Related
  9. Dual IL-17A and IL-17F neutralisation by bimekizumab in psoriatic arthritis: evidence from preclinical experiments and a randomised placebo-controlled clinical trial that IL-17F contributes to human chronic tissue inflammation · Sophie Glatt · 2017 · 268 citations · Cited by this paper
  10. Effect of methotrexate on endothelial function in psoriasis patients · 2026 · Related
  11. Bimekizumab versus Adalimumab in Plaque Psoriasis · Richard Bruce Warren · 2021 · 251 citations · Cited by this paper
  12. Evaluation of the clinical applicability of artificial intelligence in determining systemic therapy indications and treatment selection in psoriasis · 2026 · Related
  13. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning · Caitriona Ryan · 2015 · 237 citations · Cited by this paper
  14. Long-term benefits of upadacitinib for Atopic Dermatitis: deep responses in patient-reported outcomes over 140 weeks from the Measure Up 1 and Measure Up 2 clinical trials · 2026 · Related
  15. Effectiveness and safety of bimekizumab for the treatment of plaque psoriasis: a real-life multicenter study—IL PSO (Italian landscape psoriasis) · Luigi Gargiulo · 2023 · 58 citations · Cited by this paper
  16. Distinct ocular safety profiles of dupilumab and upadacitinib in atopic dermatitis: a real-world study with ophthalmological and microbiological assessment · 2026 · Related
  17. Bimekizumab maintenance of response through 3 years in patients with moderate-to-severe plaque psoriasis: results from the BE BRIGHT open-label extension trial · Bruce E Strober · 2023 · 45 citations · Cited by this paper
  18. Recalcitrant tinea infections due to Trichophyton indotineae in the United States (2025–2026): a retrospective case series identified by real-time PCR · 2026 · Related
  19. Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis · Zara Ali · 2021 · 18 citations · Cited by this paper
  20. Safety and effectiveness of omalizumab for chronic spontaneous urticaria inadequately controlled with H1 antihistamines in Chinese adolescents: a real-world, prospective, multicenter study · 2026 · Related
  21. Multi‐failure psoriasis patients: characterization of the patients and response to biological therapy in a multicenter Italian cohort · Riccardo Viola · 2024 · 14 citations · Cited by this paper
  22. Efficacy and safety of bimekizumab in real-world psoriasis management: data from patients who are biologic-naive vs. biologic-experienced · Matteo Megna · 2024 · 11 citations · Cited by this paper
  23. Bimekizumab for the treatment of moderate to severe psoriasis: a real-world experience over 52 weeks from two Italian dermatology clinics · Edoardo Mortato · 2025 · 9 citations · Cited by this paper
  24. Effectiveness of Tildrakizumab 200 mg in Moderate-to-Severe Plaque Psoriasis: A Multicenter Real-World Study Analyzing Patient Outcomes by Weight, PASI, BMI, and Previous Therapies · Emanuele Trovato · 2025 · 8 citations · Cited by this paper
  25. Long‐term maintenance of responses to bimekizumab treatment in moderate‐to‐severe psoriasis: A real‐world comparison of Q4W versus Q8W dosing or bio‐naïve versus bio‐switched patients · Marina Onda · 2025 · 3 citations · Cited by this paper
  26. Evaluating the Efficacy of Bimekizumab Across Different Sensitive Areas in Moderate-to-Severe Psoriasis: 52-week Multicentric Real-Life Experience in Lazio, Italy · Annunziata Dattola · 2025 · 3 citations · Cited by this paper
  27. A 104‐Week Real‐World Outcome of Bimekizumab Treatment for Psoriasis: Biologic‐Naïve Versus ‐Experienced Patients · Yohei Takahashi · 2025 · 2 citations · Cited by this paper
  28. Effectiveness of Bimekizumab in Multi-Failure Psoriatic Patients: A Retrospective, Real-World Multicenter Study · Francesca Satolli · 2026 · 1 citation · Cited by this paper

Source: OpenAlex (CC0)